Stoke Therapeutics, Inc.
STOKHealthcareNASDAQBiotechnology · Last scanned May 29, 2026
Scan Results
Daily timeframeStoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. Valued at $1.97B, STOK is a small-cap name in its sector. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels.
Market Cap
$1.97B
Beta
1.20
P/E (TTM)
—
P/E (Fwd)
-10.18
EPS (TTM)
$-2.86
EPS (Fwd)
$-3.10
ROE
-45.6%
ROA
-27.2%
Cash
$343.5M
Total Debt
$3.4M
Free CF
-$88.7M
52W Change
231.3%
Annual Financials
Cash vs Debt
Stoke Therapeutics, Inc. holds $343.5M in cash against $3.4M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$88.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -45.6%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $12.4M (2022) to $184.4M (2025), reflecting a 1387% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing STOK's risk profile alongside its fundamentals and technical indicators provides a more complete picture.